Replies to post #1869 on Skye Bioscience Inc (SKYE)

[AntonChigurh]

Very good post, CJ. I like the NMUS board, no pump here. Just real talk. We are all better for it.

Why do you think they used Timolol as a baseline in their studies instead of Latanoprost? It appears what you say is true in terms of Latanoprost > timolol (https://www.ncbi.nlm.nih.gov/pubmed/8628544). That was 1996, so why would they used timolol in studies completed in 2010-2015.

Do they drugs behave differently? Is there anyway to compare the performance of THC-VHS vs Timolol and Latanoprost vs Timolol? Is there the potential for them to be used in conjunction with each other? Do they do different things?

Despite the superiority of Latanoprost as you say, it appears scientists continue to discuss the efficacy of medical marijuana and glaucoma.

--> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553646/u

If Latanoprost was all you needed to treat the majority of glaucoma cases, why would they continue the debate?

As far as Valeant and Vesneo, GLTFA. I will believe it when I see it.

As far as your concerns about their financial situation, those statements are quite standard for prospectus's. They have no revenues currently and likely for the foreseeable future, so they are required to make those disclosures.

What about the outstanding shares is concerning? The S/O is actually quite low compared to their peers, which is one of the things that makes NMUS attractive.

I look forward to your response and Vinpat's

[AntonChigurh]

'. I also realise there may be neuroprotective effects, but haven't seen any hard data on that.'

This is not true. Look harder.

GLTFA

[Vinpat]

I'm not sure why they compared it to Pilocarpine and Timolol other then those seem to be the standard drugs everyone in the sector compares them to. The studies I saw didn't show that Latanoprost to be significantly better than the others and many patients are treated with combos of drops because they lose their effectiveness or work better in combo. Nemus' candidate protects the optic nerve which is critical. Especially in Japan where glaucoma is genetic and usually not caused by IOP. Daily drops will be the thing of the past as implants have been developed and Nemus has already announced that's the method they will eventually use.

Besides the 2 candidates, they also have a MRSA candidate that they've known for years is very effective and they just announced results on it.

They have fewer O/S shares than anyone in the sector and everyone on the OTC needs money and has a going concern.

[TrueTrades]

great post and the responses to it
but had to move my bid up
no pr on the patent yet has got to mean something